GLP1R and obesity due to melanocortin 4 receptor deficiency: The potential adverse effects associated with certain formulations of GLP-1 RA may limit their clinical utility, and continued surveillance will ultimately determine whether these drugs are safe enough to be used widely in the treatment of diabetes and obesity.